WO1998016646A3 - Compounds and methods for immunotherapy and diagnosis of tuberculosis - Google Patents

Compounds and methods for immunotherapy and diagnosis of tuberculosis Download PDF

Info

Publication number
WO1998016646A3
WO1998016646A3 PCT/US1997/018293 US9718293W WO9816646A3 WO 1998016646 A3 WO1998016646 A3 WO 1998016646A3 US 9718293 W US9718293 W US 9718293W WO 9816646 A3 WO9816646 A3 WO 9816646A3
Authority
WO
WIPO (PCT)
Prior art keywords
tuberculosis
compounds
diagnosis
methods
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/018293
Other languages
French (fr)
Other versions
WO1998016646A2 (en
WO1998016646A9 (en
Inventor
Steven G Reed
Yasir A W Skeiky
Davin C Dillon
Antonio Campos-Neto
Raymond Houghton
Thomas S Vedvick
Daniel R Twardzik
Michael J Lodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP97910873A priority Critical patent/EP0932681A2/en
Priority to BR9712518-0A priority patent/BR9712518A/en
Priority to AU48144/97A priority patent/AU4814497A/en
Priority to JP10518456A priority patent/JP2001501832A/en
Priority to IL12938897A priority patent/IL129388A0/en
Priority to CA002268008A priority patent/CA2268008A1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO1998016646A2 publication Critical patent/WO1998016646A2/en
Publication of WO1998016646A9 publication Critical patent/WO1998016646A9/en
Publication of WO1998016646A3 publication Critical patent/WO1998016646A3/en
Priority to NO991694A priority patent/NO991694L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.
PCT/US1997/018293 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis Ceased WO1998016646A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9712518-0A BR9712518A (en) 1996-10-11 1997-10-07 Polypeptide, DNA molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, process for detecting tuberculosis in a patient, and diagnostic kit
AU48144/97A AU4814497A (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis
JP10518456A JP2001501832A (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis
IL12938897A IL129388A0 (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis
CA002268008A CA2268008A1 (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP97910873A EP0932681A2 (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis
NO991694A NO991694L (en) 1996-10-11 1999-04-09 Compounds and methods for immunotherapy and diagnosis of tuberculosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73051096A 1996-10-11 1996-10-11
US08/730,510 1996-10-11
US08/818,112 1997-03-13
US08/818,112 US6290969B1 (en) 1995-09-01 1997-03-13 Compounds and methods for immunotherapy and diagnosis of tuberculosis

Publications (3)

Publication Number Publication Date
WO1998016646A2 WO1998016646A2 (en) 1998-04-23
WO1998016646A9 WO1998016646A9 (en) 1998-07-09
WO1998016646A3 true WO1998016646A3 (en) 1998-10-08

Family

ID=27112065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018293 Ceased WO1998016646A2 (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis

Country Status (14)

Country Link
US (3) US6290969B1 (en)
EP (1) EP0932681A2 (en)
JP (1) JP2001501832A (en)
KR (1) KR20000049101A (en)
AU (1) AU4814497A (en)
BR (1) BR9712518A (en)
CA (1) CA2268008A1 (en)
CZ (1) CZ126599A3 (en)
IL (1) IL129388A0 (en)
NO (1) NO991694L (en)
PL (1) PL332878A1 (en)
TR (1) TR199901571T2 (en)
WO (1) WO1998016646A2 (en)
ZA (1) ZA978969B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849414B2 (en) 2000-01-28 2005-02-01 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6015681A (en) * 1995-07-28 2000-01-18 The United States Of America As Represented By The Secretary Of The Navy Rapid immunoassay for cariogenic bacteria
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
CA2296419A1 (en) * 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
EP1484405A1 (en) * 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
AU766093B2 (en) * 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
EP1787994A1 (en) 1998-10-08 2007-05-23 Statens Serum Institut TB vaccine and diagnostic based on antigens from M. tuberculosis cell
AU6480999A (en) 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
ES2326257T3 (en) 1999-05-04 2009-10-06 The University Of Medicine And Dentistry Of New Jersey PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND ITS USE AS DIAGNOSTIC REAGENTS AND VACCINES.
AU779978B2 (en) 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60139963D1 (en) * 2000-06-20 2009-10-29 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
FR2818647B1 (en) * 2000-12-21 2006-09-29 Pasteur Institut IMMUNOGENIC GLYCOPEPTIDES, SCREENING, PREPARATION AND APPLICATIONS
EP1463526A4 (en) * 2001-08-02 2006-08-30 Univ New York EARLY IDENTIFICATION OF MYCOBACTERIAL DISEASE USING PEPTIDES
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
ITRM20040091A1 (en) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie QUICK IMMUNOLOGICAL TEST FOR DIAGNOSIS AND MONITORING OF TUBERCULAR INFECTION.
US7820142B2 (en) 2004-09-30 2010-10-26 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
US8475735B2 (en) * 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
NZ581306A (en) * 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
SI2457926T1 (en) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
EP2305701A1 (en) 2005-07-01 2011-04-06 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
US20070081944A1 (en) * 2005-09-30 2007-04-12 Reed Steven G Iontophoresis apparatus and method for the diagnosis of tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITION AND METHODS FOR IMMUNODOMINANT ANTIGENS
UA110103C2 (en) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. MODIFIED TUBERCULOSIS ANTIGEN
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
FR3048286B1 (en) * 2016-02-26 2021-01-22 Omunis IMMUNOGENIC PEPTIDES AND THEIR USE
JP2019517577A (en) * 2016-05-27 2019-06-24 エトゥビクス コーポレーション Neoepitope vaccine composition and method of using the same

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244539A1 (en) * 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) * 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
WO1992021758A1 (en) * 1991-06-07 1992-12-10 Institut Pasteur Mycobacterium proteins and applications
WO1994000493A1 (en) * 1992-06-29 1994-01-06 Archana Kapoor Membrane-associated immunogens of mycobacteria
WO1995001440A1 (en) * 1993-07-02 1995-01-12 Statens Seruminstitut Diagnostic skin test for tuberculosis
WO1995001441A1 (en) * 1993-07-02 1995-01-12 Statens Serumsinstitut Tuberculosis vaccine
WO1995031216A1 (en) * 1994-05-18 1995-11-23 Medical Research Council Vaccine against mycobacterial infections
WO1996015241A2 (en) * 1994-11-14 1996-05-23 Merck & Co., Inc. A polynucleotide tuberculosis vaccine
WO1996023885A1 (en) * 1995-02-01 1996-08-08 Institut Pasteur Mycobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis
WO1997009429A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533754A (en) * 1895-02-05 Elliott j
AU5856073A (en) 1973-06-28 1975-01-30 Toru Tsumits Tuberculin active proteins and peptides
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4876089A (en) 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4689397A (en) 1985-08-12 1987-08-25 Scripps Clinic And Research Foundation Synthetic polypeptides for detecting mycobacterial infections
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US4976958A (en) 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5108745B1 (en) 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1991004272A1 (en) 1989-09-19 1991-04-04 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
EP0419355B1 (en) 1989-09-19 2000-02-09 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
SE9001105D0 (en) 1990-03-27 1990-03-27 Astra Ab NEW METHODS FOR DIAGNOSIS OR TUBERCULOSIS
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
AU650065B2 (en) 1990-09-06 1994-06-09 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Inhibitor of lymphocyte response and immune-related disease
CA2095855C (en) 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
WO1992016628A1 (en) 1991-03-25 1992-10-01 N.V. Innogenetics S.A. Polypeptides from mycobacterium paratuberculosis
RU2024021C1 (en) 1991-05-05 1994-11-30 Научно-исследовательский институт хирургии Восточно-Сибирского филиала СО РАМН Method of tuberculosis diagnosis
DE4116249A1 (en) 1991-05-17 1992-11-19 Biotechnolog Forschung Gmbh HYBRID PLASMIDE FOR M. TUBERCULOSIS ANTIGEN, E. COLI AS A HOST AND ANTIGEN
GB9111291D0 (en) 1991-05-24 1991-07-17 Medical Res Council Diagnostic peptides
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
ES2105262T3 (en) 1992-05-18 1997-10-16 Minnesota Mining & Mfg PHARMACY SUPPLY DEVICE THROUGH THE MUCOSAS.
NL9202197A (en) 1992-12-17 1994-07-18 Kreatech Biotech Bv Method and device for identifying a mycobacterium species responsible for mycobacterial infection.
JPH08505625A (en) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート Induction of cytotoxic T lymphocyte response
US5616500A (en) 1993-04-30 1997-04-01 The United States Of America As Represented By The Department Of Health & Human Services Trichohyalin and transglutaminase-3 and methods of using same
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
ES2313719T3 (en) 1993-11-23 2009-03-01 The Regents Of The University Of California ABUNDANT EXTRACELLULAR PRODUCTS AND PROCEDURE OF PRODUCTION AND USE OF THE SAME.
DE4446509A1 (en) 1994-12-24 1996-06-27 Sel Alcatel Ag Method for producing conductor tracks on a substrate having depressions
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU706367B2 (en) 1995-03-13 1999-06-17 Astra Aktiebolag New DNA molecules
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997033909A2 (en) 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100797876B1 (en) 1998-04-07 2008-01-24 코릭사 코포레이션 Fusion protein of Mycobacterium tuberculosis antigen and its use
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU779978B2 (en) 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60139963D1 (en) 2000-06-20 2009-10-29 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244539A1 (en) * 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) * 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
WO1992021758A1 (en) * 1991-06-07 1992-12-10 Institut Pasteur Mycobacterium proteins and applications
WO1994000493A1 (en) * 1992-06-29 1994-01-06 Archana Kapoor Membrane-associated immunogens of mycobacteria
WO1995001440A1 (en) * 1993-07-02 1995-01-12 Statens Seruminstitut Diagnostic skin test for tuberculosis
WO1995001441A1 (en) * 1993-07-02 1995-01-12 Statens Serumsinstitut Tuberculosis vaccine
WO1995031216A1 (en) * 1994-05-18 1995-11-23 Medical Research Council Vaccine against mycobacterial infections
WO1996015241A2 (en) * 1994-11-14 1996-05-23 Merck & Co., Inc. A polynucleotide tuberculosis vaccine
WO1996023885A1 (en) * 1995-02-01 1996-08-08 Institut Pasteur Mycobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis
WO1997009429A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSEN P. ET AL.: "Identification of immunodominant antigens during infection with Mycobacterium tuberculosis", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 36, 1992, pages 823 - 831, XP002057524 *
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1993, WILEY & SONS, US, NEW YORK, XP002026411 *
ROMAIN ET AL.: "Preparation of Tuberculin antigen L", ANN. INST. PASTEUR/MICROBIOL., vol. 136B, 1985, pages 235 - 248, XP002026409 *
YOUNG ET AL.: "Screening of a recombinant mycobacterial DNA library with polyclonal antiserum and molecular weight analysis of expressed antigens", INFECTION AND IMMUNITY, vol. 55, no. 6, June 1987 (1987-06-01), pages 1421 - 1425, XP002026410 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849414B2 (en) 2000-01-28 2005-02-01 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection

Also Published As

Publication number Publication date
WO1998016646A2 (en) 1998-04-23
TR199901571T2 (en) 1999-10-21
US20090017077A1 (en) 2009-01-15
KR20000049101A (en) 2000-07-25
PL332878A1 (en) 1999-10-25
NO991694D0 (en) 1999-04-09
EP0932681A2 (en) 1999-08-04
US7989605B2 (en) 2011-08-02
BR9712518A (en) 2000-10-24
NO991694L (en) 1999-06-10
IL129388A0 (en) 2000-02-17
ZA978969B (en) 1998-04-20
US20110305721A1 (en) 2011-12-15
CZ126599A3 (en) 1999-11-17
CA2268008A1 (en) 1998-04-23
AU4814497A (en) 1998-05-11
JP2001501832A (en) 2001-02-13
US6290969B1 (en) 2001-09-18

Similar Documents

Publication Publication Date Title
WO1997009428A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
NO991694L (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2002024739A3 (en) Spas-1 cancer antigen
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
AR010517A1 (en) COMPOUNDS AND METHODS FOR TUBERCULOSIS IMMUNOTHERAPY AND DIAGNOSIS
CY1108864T1 (en) UNIONS FOR IMMUNOTHERAPY AND TYPE DIAGNOSIS AND METHODS OF USE
AU4863490A (en) Polypeptides, antigens or vaccines protective against babesiosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180501.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2268008

Country of ref document: CA

Ref document number: 2268008

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1998 518456

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-1265

Country of ref document: CZ

Ref document number: PA/a/1999/003392

Country of ref document: MX

Ref document number: 1019997003181

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 335268

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997910873

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999/01571

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1997910873

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-1265

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997003181

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-1265

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019997003181

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997910873

Country of ref document: EP